Neumora Therapeutics (NMRA) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Rallybio (RLYB) has outperformed Neumora Therapeutics (NMRA) over the past year, gaining 268.7% versus a loss of 75.3%. Rallybio is the larger company by market cap ($90.3 million vs $90.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NMRA | RLYB |
|---|---|---|
| Share price | $0.4798 | $16.99 |
| Market cap | $90.15M | $90.26M |
| 1-day change | +2.46% | +0.35% |
| YTD return | -73.20% | +209.58% |
| 1-year return | -75.27% | +268.71% |
| 5-year return | — | -86.36% |
| P/E ratio (TTM) | — | 2.12 |
| EPS (TTM) | $-1.23 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.65 | $17.57 |
| 52-week low | $0.45 | $3.67 |
| Distance from 52-week high | -86.85% | -3.32% |
| Analyst consensus | none | — |
| Avg. price target upside | +1179.70% | — |
| Average volume | 1.19M | 21.33K |
| Shares outstanding | 187.90M | 5.31M |
| Employees | 63 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed NMRA by 344.0 percentage points over the past year.
About Neumora Therapeutics
NMRA stock →Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Healthcare · Biotechnology · 63 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Healthcare · Biotechnology · 7 employees
NMRA vs RLYB FAQ
Which is bigger, Neumora Therapeutics or Rallybio?
Rallybio (RLYB) is larger, with a market capitalization of $90.26M compared with $90.15M for Neumora Therapeutics (NMRA).
Which stock has performed better over the past year, NMRA or RLYB?
RLYB returned +268.71% over the past 12 months, compared with -75.27% for NMRA (price return, excluding dividends). Past performance does not predict future results.
Are Neumora Therapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.